JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ: MIRM ) with a Overweight and raises the price target from $115 to $125.